KYOWA KIRIN, INC

Lobbying for KYOWA KIRIN, INC · Pharmaceutical company

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · New Jersey · House · Senate · $90,000.00 expenses · posted Jul 18, 2025

Lobbying activity 2

Pharmacy

FDA modernization policy issues. General issues related to rare disease and clinical trials. General issues related to diagnostics for patients with rare diseases. Issues related to drug pricing. Issues related to reform of pharmacy benefit managers. Issues related to trade. Issues related to Newborn Screening and Genetic Testing.

Trade (domestic/foreign)

Issues related to trade.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.